Free Trial

Pacific Biosciences of California Q1 2024 Earnings Report

Pacific Biosciences of California logo
$1.19 -0.08 (-6.30%)
As of 04:00 PM Eastern

Pacific Biosciences of California EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.26
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Pacific Biosciences of California Revenue Results

Actual Revenue
$38.81 million
Expected Revenue
$38.78 million
Beat/Miss
Beat by +$30.00 thousand
YoY Revenue Growth
N/A

Pacific Biosciences of California Announcement Details

Quarter
Q1 2024
Time
N/A
Remove Ads

Pacific Biosciences of California Earnings Headlines

Cathie Wood’s ARK Investment bought 899K shares of PacBio today
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Jim Gibson to join PacBio as Chief Financial Officer
Cathie Wood’s ARK Investment bought 415K shares of PacBio today
See More Pacific Biosciences of California Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pacific Biosciences of California? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pacific Biosciences of California and other key companies, straight to your email.

About Pacific Biosciences of California

Pacific Biosciences of California (NASDAQ:PACB) designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

View Pacific Biosciences of California Profile

More Earnings Resources from MarketBeat